Ratio Examination: Ionis Pharmaceuticals Inc (IONS)’s Price-to-Cash and Price-to-Free Cash Flow

Ulysses Smith

Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.

In the latest session, Ionis Pharmaceuticals Inc (NASDAQ: IONS) closed at $68.4 up 3.95% from its previous closing price of $65.8. In other words, the price has increased by $3.95 from its previous closing price. On the day, 3.0 million shares were traded. IONS stock price reached its highest trading level at $68.41 during the session, while it also had its lowest trading level at $65.97.

Ratios:

For a deeper understanding of Ionis Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.86 and its Current Ratio is at 2.87. In the meantime, Its Debt-to-Equity ratio is 3.13 whereas as Long-Term Debt/Eq ratio is at 2.11.

On September 03, 2025, BMO Capital Markets Upgraded its rating to Outperform which previously was Market Perform but kept the price unchanged to $70.

Morgan Stanley Upgraded its Equal-Weight to Overweight on July 31, 2025, while the target price for the stock was maintained at $62.

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 01 ’25 when WENDER JOSEPH H sold 16,800 shares for $65.50 per share. The transaction valued at 1,100,385 led to the insider holds 92,035 shares of the business.

Swayze Eric sold 14,142 shares of IONS for $934,662 on Oct 01 ’25. The EVP Research now owns 37,302 shares after completing the transaction at $66.09 per share. On Oct 02 ’25, another insider, Swayze Eric, who serves as the EVP Research of the company, sold 12,972 shares for $66.23 each. As a result, the insider received 859,082 and left with 37,302 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IONS now has a Market Capitalization of 10902360064 and an Enterprise Value of 10593392640. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.54 while its Price-to-Book (P/B) ratio in mrq is 17.24. Its current Enterprise Value per Revenue stands at 11.221 whereas that against EBITDA is -41.515.

Stock Price History:

The Beta on a monthly basis for IONS is 0.32, which has changed by 0.80427325 over the last 52 weeks, in comparison to a change of 0.16766965 over the same period for the S&P500. Over the past 52 weeks, IONS has reached a high of $66.25, while it has fallen to a 52-week low of $23.95. The 50-Day Moving Average of the stock is 32.30%, while the 200-Day Moving Average is calculated to be 77.96%.

Shares Statistics:

For the past three months, IONS has traded an average of 2.43M shares per day and 2229960 over the past ten days. A total of 159.20M shares are outstanding, with a floating share count of 158.16M. Insiders hold about 0.77% of the company’s shares, while institutions hold 106.68% stake in the company. Shares short for IONS as of 1757894400 were 11972594 with a Short Ratio of 4.93, compared to 1755216000 on 10785168. Therefore, it implies a Short% of Shares Outstanding of 11972594 and a Short% of Float of 9.9700004.

Earnings Estimates

. The current rating of Ionis Pharmaceuticals Inc (IONS) reflects the combined expertise of 8.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$1.11, with high estimates of -$0.95 and low estimates of -$1.37.

Analysts are recommending an EPS of between -$1.63 and -$2.49 for the fiscal current year, implying an average EPS of -$1.92. EPS for the following year is -$1.89, with 11.0 analysts recommending between -$0.46 and -$3.17.

Revenue Estimates

A total of 19 analysts believe the company’s revenue will be $131.75M this quarter.It ranges from a high estimate of $172.61M to a low estimate of $111.1M. As of. The current estimate, Ionis Pharmaceuticals Inc’s year-ago sales were $134MFor the next quarter, 19 analysts are estimating revenue of $145.21M. There is a high estimate of $218M for the next quarter, whereas the lowest estimate is $120.54M.

A total of 24 analysts have provided revenue estimates for IONS’s current fiscal year. The highest revenue estimate was $961.6M, while the lowest revenue estimate was $832.78M, resulting in an average revenue estimate of $866.36M. In the same quarter a year ago, actual revenue was $705MBased on 23 analysts’ estimates, the company’s revenue will be $900.64M in the next fiscal year. The high estimate is $1.15B and the low estimate is $687.38M.

DwinneX
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.